Breast disease: benign and malignant.

[1]  S. Orel,et al.  Who should have breast magnetic resonance imaging evaluation? , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Dobson.  Breast cancer incidence in US has fallen for first time in 20 years , 2007, BMJ : British Medical Journal.

[3]  R. Dobson.  Use of drug treatment services in England is rising , 2007, BMJ : British Medical Journal.

[4]  A. Rosenberg,et al.  Idiopathic granulomatous mastitis masquerading as carcinoma of the breast: a case report and review of the literature , 2007, International seminars in surgical oncology : ISSO.

[5]  M. Baslaim,et al.  Idiopathic Granulomatous Mastitis: A Heterogeneous Disease with Variable Clinical Presentation , 2007, World Journal of Surgery.

[6]  C. Key,et al.  Benign Breast Biopsy Diagnosis and Subsequent Risk of Breast Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.

[7]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[8]  M. Berger,et al.  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. , 2006, The New England journal of medicine.

[9]  J. Reis-Filho,et al.  Non-operative breast pathology: lobular neoplasia , 2006, Journal of Clinical Pathology.

[10]  E. Perez,et al.  Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer. , 2006, The oncologist.

[11]  Norman Wolmark,et al.  Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. , 2006, JAMA.

[12]  Corinne Balleyguier,et al.  Benign Breast Diseases , 2005, Journal of Mammary Gland Biology and Neoplasia.

[13]  E. Saettler,et al.  SOGC CLINICAL PRACTICE GUIDELINEMastalgia , 2006 .

[14]  青儀 健二郎,et al.  What's going on 乳癌 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group(EBCTCG). Lancet. 2005; 365: 1687-717. PMID: 15894097.--早期乳癌に対する化学療法・内分泌療法が乳癌再発・15年生存率に及 , 2006 .

[15]  Robert A Smith,et al.  American Cancer Society Guidelines for the Early Detection of Cancer, 2006 , 2006, CA: a cancer journal for clinicians.

[16]  L. Ford,et al.  Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. , 2005, Journal of the National Cancer Institute.

[17]  M. Dowsett,et al.  Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. , 2005, The New England journal of medicine.

[18]  Greg Yothers,et al.  Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. , 2005, The New England journal of medicine.

[19]  Y Wang,et al.  Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials , 2005, The Lancet.

[20]  K. Offit,et al.  Hereditary cancer predisposition syndromes. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  S. Zurrida,et al.  Breast cancer: a practical guide , 2005 .

[22]  A. Jemal,et al.  Annual report to the nation on the status of cancer, 1975–2001, with a special feature regarding survival , 2004, Cancer.

[23]  Norman Wolmark,et al.  Pathologic findings from the National Surgical Adjuvant Breast and Bowel Project , 2004, Cancer.

[24]  I. B. Bender.  Paget's disease. , 2003, Journal of endodontics.

[25]  A. Jemal,et al.  Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. , 2003, Journal of the National Cancer Institute.

[26]  R. Langer,et al.  Influence of Estrogen Plus Progestin on Breast Cancer and Mammography in Healthy Postmenopausal Women: The Women's Health Initiative Randomized Trial , 2003 .

[27]  Donald L Weaver,et al.  Revision of the American Joint Committee on Cancer staging system for breast cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  F. Dirbas,et al.  Clinical Management of Breast Pain: A Review , 2002, Obstetrical & gynecological survey.

[29]  N. Wolmark,et al.  Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the National Surgical Adjuvant Breast and Bowel Project experience. , 2001, Seminars in oncology.

[30]  J. Manson,et al.  Clinical practice. Postmenopausal hormone-replacement therapy. , 2001, The New England journal of medicine.

[31]  H. Nonaka,et al.  Mammary duct ectasia in children presenting bloody nipple discharge: a case in a pubertal girl. , 2001, Journal of pediatric surgery.

[32]  T. Fleming,et al.  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.

[33]  Darrell N. Smith,et al.  Galactography-guided Wire Localization of an Intraductal Papilloma: Case Report , 2001 .

[34]  J. Meyer,et al.  Case report: galactography-guided wire localization of an intraductal papilloma. , 2001, Clinical radiology.

[35]  S G Orel,et al.  MR imaging of the breast. , 2000, Radiologic clinics of North America.

[36]  Robert A Smith,et al.  American Cancer Society guidelines for the early detection of cancer , 2000, CA: a cancer journal for clinicians.

[37]  J. Elmore,et al.  Breast Symptoms among Women Enrolled in a Health Maintenance Organization: Frequency, Evaluation, and Outcome , 1999, Annals of Internal Medicine.

[38]  S G Orel,et al.  High-resolution MR imaging for the detection, diagnosis, and staging of breast cancer. , 1998, Radiographics : a review publication of the Radiological Society of North America, Inc.

[39]  D. Berry,et al.  Determining carrier probabilities for breast cancer-susceptibility genes BRCA1 and BRCA2. , 1998, American journal of human genetics.

[40]  A. Morabia,et al.  Epidemiology of benign breast disease, with special attention to histologic types. , 1997, Epidemiologic reviews.

[41]  M. Greene,et al.  Genetics of breast cancer. , 1997, Mayo Clinic proceedings.

[42]  C. Redmond,et al.  Base-line quality-of-life assessment in the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial. , 1995, Journal of the National Cancer Institute.

[43]  W D Plummer,et al.  Long-term risk of breast cancer in women with fibroadenoma. , 1994, The New England journal of medicine.

[44]  A. Srivastava,et al.  Efficacy of low fat diet in the treatment of benign breast disease. , 1994, The National medical journal of India.

[45]  K. Martin,et al.  Postmenopausal hormone-replacement therapy. , 2001, The New England journal of medicine.

[46]  B Fisher,et al.  Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. , 1993, The New England journal of medicine.

[47]  N. Risch,et al.  Age at onset as an indicator of familial risk of breast cancer. , 1990, American journal of epidemiology.

[48]  M. Gail,et al.  Projecting individualized probabilities of developing breast cancer for white females who are being examined annually. , 1989, Journal of the National Cancer Institute.

[49]  L. C. Russell.  Caffeine restriction as initial treatment for breast pain. , 1989, The Nurse practitioner.

[50]  C. Key,et al.  Prevalence of benign, atypical, and malignant breast lesions in populations at different risk for breast cancer. A forensic autopsy study , 1987, Cancer.

[51]  W D Dupont,et al.  Risk factors for breast cancer in women with proliferative breast disease. , 1985, The New England journal of medicine.

[52]  A. Forrest,et al.  Mammary duct ectasia , 1983, The British journal of surgery.

[53]  V. Devita,et al.  Cancer : Principles and Practice of Oncology , 1982 .

[54]  F. Rosato,et al.  Diseases of the Breast , 1972 .